Med Ed Report briefs—March 2012

Share this article:

FDA commissioner Margaret Hamburg told a House committee in February that FDA conflict of interest (COI) rules do not need to be relaxed. Hamburg cited FDA data showing that the percentage of COI waivers and advisory committee vacancies has stayed low.

Med-IQ, an accredited CME provider, said its performance-improvement CME initiative in multiple sclerosis was approved as part of the American Board of Psychiatry and Neurology's maintenance-of-certification program.

The American Medical Student Association will launch its 2011-2012 PharmFree Scorecard on March 8 as part of its Annual Convention in Houston.

Pharma companies dedicate 1.9% of their med-ed FTEs and budget to the Asia-emerging areas, while device companies allocate 7.5% of their med-ed FTEs and 6.4% of their med-ed budget to these areas, according to research by Best Practices, LLC.

The American College of Physicians (ACP) and CECity are using a pilot among diabetic patients in ACP state chapters to test the ability of CECity's cloud-based MedConcert to improve patient-care processes and outcomes.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?